Dr Rajeentheran Urology Stone, Urodynamics, Urooncology and Male Health

Dr Rajeentheran Urology Stone, Urodynamics, Urooncology and Male Health Urology Services, Urological Surgery, Urodynamic Services Urology Services, Urological Surgery, Urodynamic services.

Newer Medical Technologies In Medical Inflation — Dr Rajeentheran Suntheralingam
08/12/2025

Newer Medical Technologies In Medical Inflation — Dr Rajeentheran Suntheralingam

Dr Rajeentheran says while newer surgical technologies offer promising advancements, some may not significantly improve outcomes compared to established methods, potentially leading to increased costs and complexity without demonstrable benefits.

Controversies on PSA and Prostate Cancer Screening continues......When it comes to prostate cancer screening, not everyt...
06/12/2025

Controversies on PSA and Prostate Cancer Screening continues......

When it comes to prostate cancer screening, not everything that counts can be counted

“Not everything that counts can be counted, and not everything that can be counted counts.” Few statements capture the challenge of prostate cancer screening

In a rebuttal to paediatric surgeon Dr Dayang Anita’s criticism of the parallel pathway for specialisation, urologist Dr...
15/04/2024

In a rebuttal to paediatric surgeon Dr Dayang Anita’s criticism of the parallel pathway for specialisation, urologist Dr Rajeentheran clarifies several misconceptions, including non-equivalency between the parallel pathway and local Master’s programmes.

In a rebuttal to paediatric surgeon Dr Dayang Anita's criticism of the parallel pathway for specialisation, urologist Dr Rajeentheran clarifies several misconceptions, including non-equivalency between the parallel pathway and local Master's programmes.

Urologist Dr Rajeentheran says MQA set a wrong precedent by allowing single universities MQA approval to conduct special...
15/04/2024

Urologist Dr Rajeentheran says MQA set a wrong precedent by allowing single universities MQA approval to conduct specialist training programmes. The Medical Act should be amended to enable professional bodies to form a Board of Specialist training programme.

Urologist Dr Rajeentheran says MQA set a wrong precedent by allowing single universities MQA approval to conduct specialist training programs. The Medical Act should be amended to enable professional bodies to form a Board of Specialist training program.

FDA Has Approved The First Drug for Von Hippel-Lindau-Associated Tumors— Objective response or stable disease in 100% of...
16/08/2021

FDA Has Approved The First Drug for Von Hippel-Lindau-Associated Tumors
— Objective response or stable disease in 100% of renal cell carcinomas

The FDA has approved the first therapy for cancers associated with von Hippel-Lindau (VHL) disease.
Belzutifan (Welireg) targets hypoxia-inducible factor 2α, which drives growth of malignant and benign tumors in VHL. In the absence of approved systemic therapies, most patients with VHL undergo multiple surgeries in their lifetime to remove renal cell carcinoma (RCC) and other VHL-associated tumors. The approval encompasses VHL-associated RCC, central nervous system (CNS) hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery.

FDA Approves First Drug for Von Hippel-Lindau-Associated Tumors - Urologist Selangor Dr Rajeentheran

FDA Grants Accelerated Approval to Sacituzumab Govitecan for Metastatic Urothelial Cancer The FDA has granted accelerate...
19/04/2021

FDA Grants Accelerated Approval to Sacituzumab Govitecan for Metastatic Urothelial Cancer

The FDA has granted accelerated approval to sacituzumab govitecan (Trodelvy) to treat patients with locally advanced or metastatic urothelial carcinoma after having received a PD-1 / PD-L1 inhibitor and platinum-based chemotherapy.

This is based on the results of the phase 2 TROPHY-U-01 trial.

This approval makes sacituzumab govitecan the first drug with a third-line indication for advanced bladder cancer.

The bladder cancer indication comes just a week after the FDA granted full approval of sacituzumab govitecan for unresectable or metastatic triple-negative breast cancer.

For more info, see the following link:

https://www.urology.com.my/fda-grants-accelerated-approval-to-sacituzumab-govitecan-for-metastatic-urothelial-cancer/

FDA Grants Accelerated Approval to Sacituzumab Govitecan for Metastatic Urothelial Cancer - Urologist Selangor Dr Rajeentheran

Erector spinae plane block for severe renal colic painThis pilot clinical feasibility study was recently published in th...
05/04/2021

Erector spinae plane block for severe renal colic pain
This pilot clinical feasibility study was recently published in the International Journal of Clinical Practices by a Turkish Group from the Ataturk University School of Medicine, Erzurum, Turkey.

Note that this is yet a standard practice, and currently a pilot feasibility study. We have to await for more studies, but it does seem promising for persistent severe renal or ureteric colic refractory to systemic NSAID or opioids.

The key results of this study showed that:

1. In the erector spinae plane block (ESP) group, the visual analogue scale (VAS) scores were significantly lower than the NSAID group at 5, 15, 30, 45 and 60 minutes after the procedure (P < .001).

2. Opioid consumption was significantly higher in the NSAID group compared with the ESP group (10/20 vs 0/20, respectively; P < .001).

3. Patient satisfaction was significantly higher in the ESP group (P < .001).

See the following link:

Erector spinae plane block for severe renal colic pain - Urologist Selangor Dr Rajeentheran

03/04/2021

Tivozanib has now been added to NCCN guidelines for Renal Cell Carcinoma treatment

Tivozanib (Fotivda) has been added to the National Comprehensive Cancer Network (NCCN) guidelines for use as a subsequent therapy following first-line treatment recommendations for patients with clear cell renal cell carcinoma (RCC), according to AVEO Oncology, the developer of the oral, next-generation VEGF tyrosine kinase inhibitor.

The FDA approved tivozanib on March 10, 2021, for the treatment of adult patients with relapsed or refractory advanced RCC who have received 2 or more prior systemic therapies, based on data from the phase 3 TIVO-3 trial.

Results from TIVO-3 presented during the 2020 ASCO Virtual Scientific Program showed that treatment with tivozanib led to a significant improvement in progression-free survival (PFS) compared with sorafenib (Nexavar), with similar overall survival (OS), in patients with relapsed/refractory metastatic RCC.

https://www.urology.com.my/tivozanib-has-now-been-added-to-the-nccn-guidelines-for-renal-cell-carcinoma/

How to Prevent Kidney Stones:Increasing fluid intake and making dietary lifestyle changes can prevent future stones or a...
03/04/2021

How to Prevent Kidney Stones:

Increasing fluid intake and making dietary lifestyle changes can prevent future stones or at least reduce the incidence of kidney stone disease.

High fluids intake is the most important factor for preventing kidney stone disease and for every 200 mL of water, the risk of stones is reduced by 13%.

From the National Kidney Foundation;

General Recommendations to prevent or at least reduce the incidence of kidney stones include:

1. Drink plenty of fluid: 2.5 - 3 liters/day

• Try to drink at least 2.5 liters of fluids a day. Water is best, although juice (other than grapefruit juice) and other beverages can add to the total.

• This includes any type of fluid such as water, and lemonade which have been shown to have a beneficial effect with the exception of grapefruit juice and soda. Citrous fruits have been shown to be advantageous as citrate has been shown to reduce aggregation of crystals in forming stones.

• Limit your intake of caffeine-containing beverages like coffee, tea, and cola to one or two cups a day, since caffeine acts as a diuretic, causing your body to lose fluids too quickly. These beverages also contain oxalates.

• A good gauge of whether or not you are drinking enough fluids is urine color. Except for the first thing in the morning—when urine tends to be more concentrated—it should be pale in color. If your urine is dark yellow, that's an indication to drink more fluids.

• The other good gauge is thirst. If you are thirsty it would usually mean that you have inadequate fluid intake.

• This will help produce less concentrated urine and ensure a good urine volume of at least 2.5L/day

• If you are hesitant to drink too much during the day because you have a bladder control problem, discuss this concern with your doctor.

2. Limit foods with high oxalate content

• Spinach, many berries, chocolate, wheat bran, nuts, beets, tea and rhubarb should be eliminated from your diet intake

3. Eat enough dietary calcium

• Three servings of dairy per day will help lower the risk of calcium stone formation. Eat with meals.

4. Avoid extra calcium supplements

• Calcium supplements should be individualized by your physician and registered kidney dietitian

5. Eat a moderate amount of protein

• High protein intakes will cause the kidneys to excrete more calcium therefore this may cause more stones to form in the kidney

6. Avoid high salt intake

• High sodium intake increases calcium in the urine which increases the chances of developing stones

• Low salt diet is also important to control blood pressure.

7. Avoid high doses of vitamin C supplements

• It is recommend to take 60mg/day of vitamin C based on the US Dietary Reference Intake

• Excess amounts of 1000mg/day or more may produce more oxalate in the body

For more detailed discussions on this, see the following link:

Prevention of Kidney Stones, a brief summary - Urologist Selangor Dr Rajeentheran

FDA Approves Tivozanib for Relapsed/Refractory Advanced Renal Cell Carcinoma The FDA approved the angiogenesis inhibitor...
03/04/2021

FDA Approves Tivozanib for Relapsed/Refractory Advanced Renal Cell Carcinoma

The FDA approved the angiogenesis inhibitor tivozanib (Fotivda) for relapsed/refractory advanced renal cell carcinoma (RCC).

Tivozanib is now the first approved therapy for patients who received two or more prior lines of therapy for advanced RCC.

Support for the approval came primarily from the randomized TIVO-3 trial that showed tivozanib improved progression-free survival (PFS) as compared with sorafenib (Nexavar), another angiogenesis inhibitor.

It is the first treatment to improve PFS after two or three prior lines of therapy.

The TIVO-3 trial involved 350 patients who had received two or three prior lines of therapy for relapsed/refractory advanced RCC. Investigators in 12 countries randomized the patients to the two antiangiogenic agents, and treatment continued until disease progression or development of unacceptable toxicity.

The primary endpoint was PFS, and data analysis showed a median PFS of 5.6 months with tivozanib versus 3.9 months with sorafenib. The difference represented a 27% reduction in the hazard for disease progression or death with tivozanib (95% CI 0.56-0.75, P=0.016). Median overall survival did not differ significantly between treatment groups, but was numerically higher with sorafenib (19.2 vs 16.4 months, HR 0.97, 95% CI 0.75-1.24). Objective response rates were 18% with tivozanib and 8% with sorafenib.

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma - Urologist Selangor Dr Rajeentheran

FDA Approves Mirabegron For ChildrenThe U.S. Food and Drug Administration on 25th March 2021 approved a new indication f...
03/04/2021

FDA Approves Mirabegron For Children

The U.S. Food and Drug Administration on 25th March 2021 approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

Myrbetriq (mirabegron extended-release tablets) is now approved for treatment of neurogenic detrusor overactivity, common in patients with spina bifida, in children 3 years and older. The expanded indication approval also applied to Myrbetriq Granules (mirabegron for extended-release oral suspension), which are intended for children who may have difficulty swallowing tablets.

Myrbetriq had earlier been indicated and approved for overactive bladder in adult patients.

It has also been 1 year since FDA approved solifenacin succinate, the first treatment of NDO in pediatric patients aged 2 years and older.

Approval of Myrbetriq for this indication was based on a phase 3 study of 86 patients ages 3 to 17 years. After 24 weeks of treatment with Myrbetriq, researchers found patients improved in maximum cystometric capacity, number of detrusor contractions, volume of urine held until the first detrusor contraction, and the number of daily urine leakage episodes.

FDA Approves Mirabegron For Children % - Urologist Selangor Dr Rajeentheran

Address

Petaling Jaya
47400

Opening Hours

Monday 09:00 - 17:00
Tuesday 09:00 - 17:00
Wednesday 09:00 - 17:00
Thursday 09:00 - 17:00
Friday 09:00 - 17:00
Saturday 09:00 - 12:30

Telephone

+60377267677

Alerts

Be the first to know and let us send you an email when Dr Rajeentheran Urology Stone, Urodynamics, Urooncology and Male Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr Rajeentheran Urology Stone, Urodynamics, Urooncology and Male Health:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category